25

20

30

1. A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula

$$Q_4H$$
 Q_4H
 Q_1H
 R_2
 Q_1
 R_4
 R_3
 R_6
 Q_1
 Q_1
 Q_1
 Q_2
 Q_1
 Q_2
 Q_3
 Q_4
 Q

wherein X is R_1 , OR_1 , or SR_1 ;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alky of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an afalkyl of 7 to 12 carbon atoms;

(v) ph¢nyl;

(vi) sybstituted phenyl


$$Z_{i}$$
 Z_{ii}
 Z_{iii}
 Z_{iii}

wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN,

= 15 THE THE THE THE

30

wherein R, is



wherein Z_i , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphoneutrophil (PMN) inflammation in a subject is modulated.

- 2. The method of claim 1, wherein said method is performed in vitro.
- 3. The method of claim 1, wherein said method is performed in vivo.

20

25

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula

5

THE PROPERTY OF THE PARTY WAS AND WAS

KIL LOI

20

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

(i)

a hydrogen atom;

an alkylof 1 to 8 carbons atoms, inclusive, which may (ii) be straight chain or branched;

 Z_{iii}

a cycloalkyl of 3 to 10 carbon atoms; (iii)

(iv) an aralkyl of 7 to 12 carbon atoms;

phenyl; (v)

substituted phenyl (vi)

25

30

wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to (vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO₂ or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O/S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is Q or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ is


- (a) /H
- (b) / an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein/R₅ is

5

20

25



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

20

THE PERSON IN

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoreutrophil (PMN) inflammation is treated in a subject.

25

- 5. The/method of claim 1, wherein said method is performed in vitro.
- 6. The method of claim 1, wherein said method is performed in vivo.

7. A method for modulating a disease or condition associated with phosphlipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula

$$Q_4H$$
 Q_3H
 Q_3H
 Q_1
 Q_1
 Q_1
 Q_2
 Q_3
 Q_4
 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

(i) a hydrogen atom;


(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) / substituted phenyl



wherein Z_{ii} , Z_{ii} , Z_{iv} and Z_{v} are each independently selected from -NO₂, -CN,

5

20

25

(vii)

a detectable label molecule; or

(viii)

a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8/carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ i

(a)

H;

an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R5 is

20

ira pa

ļ.d

1

O

₌ 15

5

25

 Z_{i} Z_{ii} Z_{iii}

20

5

wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to Carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

- (a) H;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

25

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

- 8. The method of claim 7, wherein said method is performed in vitro.
- 9. The method of claim 7, wherein said method is performed in vivo.

10. A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula

5

10 **≖** 15 ļ4 THE WALLS

· 20


25

30

$$Q_4H$$
 Q_3H
 R_2
 Q_1
 R_4
 R_5
 R_5
 R_7

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

- (i) a hydrogen atom;
- an alkyl/of 1 to/8 carbons atoms, inclusive, which may (ii) be straight chain or branched;
- a cycloalkyl of 3 to 10 carbon atoms; (iii)
- (iv) an aralky of 7 to 12 carbon atoms;
- phenyl; (v)
- (vi) substituted phenyl



wherein Z_i , $\not Z_{ii}$, Z_{iv} and Z_v are each independently selected from -NO₂, -CN, $-C(=O)-R_{x}$, $-SO_{3}H$, a hydrogen atom, halogen, methyl, $-OR_{x}$, wherein R_{x} is 1 to

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -0- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;


wherein R₄ is

(a) 1/1:

(b) / an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is

25



T.

ĮĎ,

20

≢ 15

wherein Z_i , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z_b is cyano, nitro or a halogen;

wherein R₆ is

(a)

H;

(b) an alkyl/from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or \$, and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

25

- 11. The method of claim 10, wherein said method is performed in vitro.
- 12. The method of claim 10, wherein said method is performed in vivo.

30

13. A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula

5

25


20

30

$$Q_4H$$
 Q_3H
 Q_3H
 Q_1
 Q_1
 Q_1
 Q_2
 Q_3
 Q_4
 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

- (i) a hydrogen/atom;
- (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;
- (iii) a cycloalkyl of 3 to 10 carbon atoms;
- (iv) an aralky/of 7, to 12 carbon atoms;
- (v) phenyl;
- (vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon

atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalky/ of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ i


H;

an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

5

20

wherein R₅ is



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsybstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

5

25

14. A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula

 Q_4H Q_3H Q_3H Q_1 Q_1 Q_1 Q_2 Q_3 Q_4 Q_4 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

(i) a hydrogen arom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain on branched;


V

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

5

20

25

(vii) a detectable label molecule; for

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R4 is

- (a) / H;
- (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;


wherein R₅ is

The first that the second man and the second man an

5

20

25



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R6 is

- (a) H;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

- 15. A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:
- a container holding a therapeutically effective amount of at least one lipoxin compound having the formula

O I I'll I'll I''ll I'''l I''' I I''' I'''' I''' I'''' I''' I'''' I''' I'''

5

20


25

<u>1</u>0 I IÑ

25

20

30



·Ziii

wherein Z_i , Z_{ii}/Z_{iii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN, $-C(=O)-R_1$, $/SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

- (vii) a detectable label molecule; or
- (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is


- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -Q- or -S=; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R4 is

- (a) H;
- (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

25

wherein R₅ is



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H

(b) /an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

.

5

O 5

20


16. A packaged pharmaceutical composition for treating phospholipase D

(PLD) initiated superoxide generation or degranulation activity in a subject, comprising:
a container holding a therapeutically effective amount of at least one lipoxin
compound having the formula

 Q_4H Q_3H Q_3H Q_1 Q_1 Q_1 Q_2 Q_3 Q_4 Q_4 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

- (i) a hydrogen arom;
- (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;
- (iii) / a cycloalkyl of 3 to 10 carbon atoms;
- (iv) / an aralkyl of 7 to 12 carbon atoms;
- (v) / phenyl;
- (vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN,

THE REPORT IN THE REPORT OF THE PARTY OF THE

5

20

25

 $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule, or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalky/of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched, or
- (e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄/is


(a) H;

/(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R₅ is

25

20



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

- (a) H;
- (b) an alky from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O of S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.

10 THE PART OF THE STREET STRE

20

25

5

Mai